BMY

#129
Bristol-Myers Squibb Company Common Stock
56.8 8 USD
+0.09%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
56.81
57.30
Range Annuel
42.52
62.89
Changement quotidien
+0.09%
Changement Mensuel
-1.44%
Evolution sur 6 mois
+15.33%
Changement Annuel
+18.87%
Clôture Précédente
56.8 3
Open
56.9 7
Low
56.8 1
High
57.3 0
Volume
999
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 116.15 B
  • Employee 33 K
  • Founded N/A
  • CEO Chris Boerner
  • Website www.bms.com
  • Headquarter Delaware, United States
  • FIGI BBG000DQLV23
  • Industry Fabricants de Médicaments — Généralités
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
15.59
ratio cours/chiffre d'affaires
2.28
Dividende par action
2.49
Rendement du dividende (%)
4.62

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

Nouvelles